Major signaling pathways, including mitogen-activated protein kinase (MEK), often characterize mutant KRAS tumor proliferation and survival, so inhibiting their signaling mechanism is a valid approach for overcoming these pathways [57]. The gene discussed is KRAS; the disease is neoplasm.